{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:55:57Z","timestamp":1787896557827,"version":"build-2784847793"},"reference-count":46,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Purpose: next-generation sequencing based comprehensive genomic profiling (CGP) is becoming common practice. Although numerous studies have shown its feasibility to identify actionable genomic alterations in most patients, its clinical impact as part of routine management across all cancers in the community remains unknown. Methods: we conducted a retrospective study of all patients that underwent CGP as part of routine cancer management from January 2013 to June 2017 at an academic community-based NCI-designated cancer center. CGP was done in addition to established first tier reflex molecular testing as per national guidelines (e.g., EGFR\/ALK for non-small cell lung cancer (NSCLC) and extended-RAS for colorectal cancer). Results: 349 tests were sent for CGP from 333 patients and 95% had at least one actionable genomic alteration reported. According to the reported results, 23.2% had a Food and Drug Administration (FDA) approved therapy available, 61.3% had an off-label therapy available and 77.9% were potentially eligible for a clinical trial. Treatment recommendations were also reviewed within the OncoKB database and 47% of them were not clinically validated therapies. The CGP results led to treatment change in only 35 patients (10%), most commonly in NSCLC. Nineteen of these patients (54% of those treated and 5% of total) had documented clinical benefit with targeted therapy. Conclusion: we demonstrate that routine use of CGP in the community across all cancer types detects potentially actionable genomic alterations in a majority of patients, however has modest clinical impact enriched in the NSCLC subset.<\/jats:p>","DOI":"10.3390\/cancers12051156","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T06:41:20Z","timestamp":1588660880000},"page":"1156","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2063-6407","authenticated-orcid":false,"given":"Aditi P.","family":"Singh","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, University of Pennsylvania\/Abramson Cancer Center, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Shum","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, NYU Langone Perlmutter Cancer Center, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Rajdev","sequence":"additional","affiliation":[{"name":"Department of Oncology, Montefiore Medical Center\/Albert Einstein College of Medicine, Bronx, NY 10467, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Montefiore Medical Center\/Albert Einstein College of Medicine, Bronx, NY 10467, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2798-7568","authenticated-orcid":false,"given":"Sanjay","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Oncology, Montefiore Medical Center\/Albert Einstein College of Medicine, Bronx, NY 10467, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Perez-Soler","sequence":"additional","affiliation":[{"name":"Department of Oncology, Montefiore Medical Center\/Albert Einstein College of Medicine, Bronx, NY 10467, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[{"name":"Department of Oncology, Montefiore Medical Center\/Albert Einstein College of Medicine, Bronx, NY 10467, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e87062","DOI":"10.1172\/jci.insight.87062","article-title":"Institutional implementation of clinical tumor profiling on an unselected cancer population","volume":"1","author":"Sholl","year":"2016","journal-title":"JCI Insight"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1200\/JCO.2017.35.15_suppl.6605","article-title":"Estimated cost of anticancer therapy directed by comprehensive genomic profiling (CGP) in a single-center study","volume":"35","author":"Signorovitch","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","article-title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","volume":"29","author":"Remon","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cllc.2017.04.004","article-title":"Genomic Profiling of Advanced Non\u2013Small Cell Lung Cancer in Community Settings: Gaps and Opportunities","volume":"18","author":"Gutierrez","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/EDBK_237863","article-title":"Biomarker Testing for Patients with Advanced Non\u2013Small Cell Lung Cancer: Real-World Issues and Tough Choices","volume":"39","author":"Pennell","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_6","unstructured":"(2020, April 16). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Non Small Cell Lung Cancer Version 3.2020 [11 February 2020]. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jmoldx.2016.10.008","article-title":"Clinical Genomic Profiling of a Diverse Array of Oncology Specimens at a Large Academic Cancer Center","volume":"19","author":"Sireci","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1634\/theoncologist.2016-0049","article-title":"Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers","volume":"21","author":"Hirshfield","year":"2016","journal-title":"Oncologist"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/annonc\/mdx786","article-title":"Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it","volume":"29","author":"Prasad","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_12","unstructured":"Institute NC (2020, April 16). Genomic Profiling Tests Cleared by FDA Can Help Guide Cancer Treatment, Clinical Trial Enrollment 2017 [29 May 2019], Available online: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2017\/genomic-profiling-tests-cancer."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1200\/jco.2014.32.15_suppl.8098","article-title":"Effect of reflex testing by pathologists on molecular testing rates in lung cancer patients: Experience from a community-based academic center","volume":"32","author":"Inal","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.18632\/oncotarget.27047","article-title":"Oncologist uptake of comprehensive genomic profile guided targeted therapy","volume":"10","author":"Nesline","year":"2019","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hilal, T., Nakazawa, M., Hodskins, J., Villano, J.L., Mathew, A., Goel, G., Wagner, L., Arnold, S.M., DeSimone, P., and Anthony, L. (2017). Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3587-8"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1158\/0008-5472.CAN-15-3043","article-title":"Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study","volume":"76","author":"Wheler","year":"2016","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1535-7163.MCT-14-1061","article-title":"On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients","volume":"14","author":"Schwaederle","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: A Precision Oncology Knowledge Base","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e18018","DOI":"10.1200\/JCO.2016.34.15_suppl.e18018","article-title":"Utility of comprehensive genomic profiling (CGP) at an NCI-designated cancer center for identifying clinically relevant genomic alterations (CRGA) and implementing genomically directed therapy (GDT)","volume":"34","author":"Hilal","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2019.37.15_suppl.3003","article-title":"Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors","volume":"37","author":"Fakih","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1200\/JCO.2018.36.15_suppl.9031","article-title":"Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model","volume":"36","author":"Pennell","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_24","unstructured":"Administration USFaD (2020, April 16). FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication, Available online: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm560040.htm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.jtho.2019.08.426","article-title":"OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC","volume":"14","author":"Langer","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.jtho.2019.08.427","article-title":"OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC","volume":"14","author":"Garassino","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"22064","DOI":"10.18632\/oncotarget.8017","article-title":"Mutation based treatment recommendations from next generation sequencing data: A comparison of web tools","volume":"7","author":"Patel","year":"2016","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1634\/theoncologist.2015-0097","article-title":"Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center","volume":"20","author":"Tafe","year":"2015","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00046","article-title":"Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board","volume":"2017","author":"Dalton","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2019-0441","article-title":"Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer","volume":"25","author":"Gupta","year":"2019","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14737159.2020.1680287","article-title":"Liquid biopsy tracking of lung tumor evolutions over time","volume":"19","author":"Russo","year":"2019","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Imperial, R., Nazer, M., Ahmed, Z., Kam, A.E., Pluard, T.J., Bahaj, W., Levy, M., Kuzel, T.M., Hayden, D.M., and Pappas, S.G. (2019). Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice. Cancers, 11.","DOI":"10.3390\/cancers11091399"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1373\/clinchem.2019.303339","article-title":"A New Era in Liquid Biopsy: From Genotype to Phenotype","volume":"66","author":"Kelley","year":"2019","journal-title":"Clin. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41698-019-0095-0","article-title":"Liquid biopsy: One cell at a time","volume":"3","author":"Vasudevan","year":"2019","journal-title":"NPJ Precis. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","article-title":"Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells","volume":"19","author":"Keller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.trsl.2019.07.003","article-title":"CTC analysis: An update on technological progress","volume":"212","author":"Batth","year":"2019","journal-title":"Transl. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_156686","article-title":"The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Delord","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13073-016-0364-2","article-title":"Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: The Princess Margaret IMPACT\/COMPACT trial","volume":"8","author":"Stockley","year":"2016","journal-title":"Genome Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of Patient Characteristics and Tumor Genomics with Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12962-019-0191-6","article-title":"Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment","volume":"17","author":"Spizzo","year":"2019","journal-title":"Cost Eff. Resour. Alloc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/13696998.2018.1549056","article-title":"Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer","volume":"22","author":"Signorovitch","year":"2018","journal-title":"J. Med. Econ."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10549-017-4580-2","article-title":"Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer","volume":"168","author":"Pezo","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/cas.14313","article-title":"Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer","volume":"111","author":"Lin","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1156\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:32:38Z","timestamp":1760362358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["cancers12051156"],"URL":"https:\/\/doi.org\/10.3390\/cancers12051156","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,4]]}}}